Your browser is no longer supported. Please, upgrade your browser.
Settings
NVET Nexvet Biopharma Public Limited Company daily Stock Chart
NVET [NASD]
Nexvet Biopharma Public Limited Company
Index- P/E- EPS (ttm)-1.75 Insider Own3.90% Shs Outstand12.15M Perf Week0.15%
Market Cap81.40M Forward P/E- EPS next Y-1.70 Insider Trans0.00% Shs Float10.60M Perf Month0.30%
Income-20.50M PEG- EPS next Q-0.38 Inst Own66.10% Short Float0.21% Perf Quarter1.36%
Sales- P/S- EPS this Y26.10% Inst Trans10.22% Short Ratio1.38 Perf Half Y81.08%
Book/sh1.78 P/B3.76 EPS next Y5.00% ROA-63.80% Target Price6.72 Perf Year35.35%
Cash/sh1.19 P/C5.61 EPS next 5Y- ROE-72.70% 52W Range2.75 - 6.76 Perf YTD79.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.68% Beta-
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low144.00% ATR0.02
Employees28 Current Ratio5.30 Sales Q/Q- Oper. Margin- RSI (14)63.73 Volatility0.16% 0.19%
OptionableNo Debt/Eq0.00 EPS Q/Q-2.80% Profit Margin- Rel Volume1.01 Prev Close6.70
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume15.88K Price6.71
Recom3.00 SMA200.33% SMA500.76% SMA20040.74% Volume15,977 Change0.15%
Apr-24-17Downgrade Credit Suisse Outperform → Neutral
Feb-04-16Initiated Credit Suisse Outperform
Jul-10-17 09:56AM  Nexvet Biopharma plc ("Nexvet") Rule 17(c) Announcement GlobeNewswire
Jul-05-17 05:30AM  Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement GlobeNewswire
Jul-03-17 03:55PM  Lifshitz&Miller LLP Announces Investigation of ARI Network Services, Inc., DuPont Fabros Technology, Inc., Nexvet Biopharma Public Limited Company, PAREXEL International Corporation, Rice Energy Inc. and SciClone Pharmaceuticals, Inc. PR Newswire
05:30AM  Nexvet Biopharma plc ("Nexvet") Supplement Announcement GlobeNewswire
Jun-21-17 09:30PM  SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Nexvet Biopharma plc and Encourages Investors to Contact the Firm for Additional Information Business Wire
Jun-20-17 01:22PM  NEXVET BIOPHARMA PLC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout Business Wire
Jun-19-17 04:07PM  WeissLaw LLP Files Class Action Lawsuit Against Nexvet Biopharma PLC PR Newswire
05:30AM  Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement GlobeNewswire
Jun-16-17 05:30AM  Nexvet Biopharma plc ("Nexvet") Rule 15 Announcement GlobeNewswire
Jun-14-17 05:30AM  Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement GlobeNewswire
Jun-07-17 12:11AM  Nexvet Biopharma plc ("Nexvet") Rule 17(b) Announcement GlobeNewswire
Jun-02-17 11:06AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Filing of a Complaint Concerning Whether the Sale of Nexvet Biopharma Public Limited Company to Zoetis Inc. for $6.72 Per Share is Fair to Shareholders Business Wire
08:30AM  Nexvet Biopharma plc ("Nexvet") Rule 17 Announcement GlobeNewswire
Jun-01-17 10:15PM  Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement GlobeNewswire
04:14PM  Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Nexvet Biopharma Public Limited Company - NVET PR Newswire
May-11-17 08:52PM  Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement GlobeNewswire
05:30AM  Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017 GlobeNewswire
Apr-17-17 09:40AM  Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma Zacks
Apr-13-17 09:02PM  Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals Business Wire +63.46%
09:24AM  Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals Business Wire
Mar-13-17 06:07AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Mar-10-17 04:40PM  AbbVie Outperforms Drug Stocks On $20.5 Billion Growth View Investor's Business Daily +11.60%
04:40PM  AbbVie Outperforms Drug Stocks On $20.5 Billion Growth View
Feb-22-17 05:30AM  Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-16-17 01:04PM  NEXVET BIOPHARMA PLC Financials
Feb-10-17 07:07AM  Q2 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied +6.62%
06:12AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
05:30AM  Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 GlobeNewswire
Dec-12-16 05:30AM  Nexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats GlobeNewswire
Dec-06-16 10:13AM  Nexvet Biopharma PLC :NVET-US: Earnings Analysis: Q1, 2017 By the Numbers : December 6, 2016 +5.79%
Nov-18-16 06:04AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission
Nov-04-16 09:37AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
07:07AM  Q1 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied
06:11AM  NEXVET BIOPHARMA PLC Files SEC form 10-Q, Quarterly Report
05:30AM  Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017 GlobeNewswire
Oct-19-16 05:30AM  Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference GlobeNewswire
Oct-04-16 06:55AM  Zomedica Appoints Two Animal Health Veterans to Board of Directors GlobeNewswire
Sep-02-16 09:38AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -10.67%
07:07AM  Q4 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied
06:07AM  NEXVET BIOPHARMA PLC Files SEC form 10-K, Annual Report
05:30AM  Nexvet Biopharma Reports Full Year Fiscal 2016 Results GlobeNewswire
Jul-20-16 05:30AM  Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference GlobeNewswire
Jun-10-16 05:02PM  Nexvet Biopharma PLC :NVET-US: Earnings Analysis: Q3, 2016 By the Numbers : June 10, 2016 Capital Cube -6.16%
05:02PM  Nexvet Biopharma PLC :NVET-US: Earnings Analysis: Q3, 2016 By the Numbers : June 10, 2016
08:25AM  Nexvet Biopharma (NVET) Jumps: Stock Moves 9.2% Higher Zacks
Jun-09-16 07:32AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +9.23%
05:30AM  Nexvet Presents Expanded Positive Clinical Data for Ranevetmab (NV-01) and Frunevetmab (NV-02) at ACVIM GlobeNewswire
Jun-03-16 06:10AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +10.53%
05:30AM  Nexvet Announces Opening of Manufacturing Facility and Production Milestone Achievement GlobeNewswire
May-27-16 05:30AM  Nexvet Provides Update on Upcoming Investor Symposium at Irish Biomanufacturing Facility GlobeNewswire +7.94%
May-26-16 06:09AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
05:30AM  Nexvet Announces Positive Results from NV-02 Pilot Field Study in Cats with Osteoarthritis GlobeNewswire
May-12-16 09:38AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
07:07AM  Q3 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied
06:13AM  NEXVET BIOPHARMA PLC Files SEC form 10-Q, Quarterly Report
05:30AM  Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2016 GlobeNewswire
May-11-16 05:30AM  Nexvet to Host Symposium at American College of Veterinary Internal Medicine (ACVIM) Forum to Present Additional NV-01 Pivotal Data in Canine Pain and Clinical Data for NV-02 in Feline Pain GlobeNewswire -5.12%
May-04-16 05:30AM  Nexvet to Host Investor Symposium at its Irish Biomanufacturing Facility GlobeNewswire
May-02-16 05:30AM  Nexvet and Zenoaq Announce PD-1 mAb Candidate for Canine Cancer GlobeNewswire
Mar-08-16 06:20AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
05:30AM  Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis GlobeNewswire
Mar-02-16 10:46AM  5 Stocks Insiders Have Been Scooping Up Lately at TheStreet
Feb-29-16 05:30AM  Nexvet to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-16-16 06:27AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
06:17AM  NEXVET BIOPHARMA PLC Files SEC form 10-Q, Quarterly Report
05:30AM  Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2016 GlobeNewswire
Feb-04-16 01:15PM  Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pets Health at 24/7 Wall St. +11.18%
07:42AM  Coverage initiated on Nexvet Biopharma by Credit Suisse
Jan-14-16 06:48AM  5 Stocks Under $10 Set to Soar at TheStreet +5.11%
Dec-29-15 03:20PM  Bill & Melinda Gates Foundation Trusts Latest Bet on China & Two Other Latest Hedge Fund Moves at Insider Monkey
Dec-08-15 05:30AM  Nexvet to Discuss Pivotal Study Success of Lead Program and Product Pipeline at Bank of America Merrill Lynch 2015 Animal Health Summit GlobeNewswire
Nov-24-15 05:30AM  Nexvet to Present at the 27th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-23-15 09:08AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +8.51%
06:00AM  Nexvet Biopharma plc (Nasdaq: NVET) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Nov-20-15 04:31PM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission
Nov-16-15 04:06PM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -15.37%
05:30AM  Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis GlobeNewswire
Nov-14-15 04:55PM  Nexvet Hosting Teleconference to Provide Update on NV-01 Pivotal Study GlobeNewswire
Nov-12-15 05:30AM  Nexvet Provides Speaker Update for Animal Health Symposium in New York City GlobeNewswire
Nov-05-15 04:09PM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi +6.26%
07:35AM  NEXVET BIOPHARMA PLC Files SEC form 10-Q, Quarterly Report
06:00AM  Nexvet Reports Financial Results for First Quarter of Fiscal Year 2016 GlobeNewswire
Oct-29-15 03:12PM  AMAG to Initiate Head-to-Head Phase III Study on Feraheme +6.36%
Oct-21-15 09:15AM  Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut
Oct-19-15 05:30AM  Nexvet Initiates Pilot Field Study of NV-02 for Feline Osteoarthritis Pain GlobeNewswire
Oct-16-15 09:00AM  CMS Hikes Medicare Rate for Genomic's Breast Cancer Test (Revised)
Oct-14-15 03:50PM  Incyte & Merck Expand Melanoma Treatment Collaboration
Oct-13-15 06:30PM  BioMarin Presents Data on Vosoritide at Medical Meeting
Oct-09-15 02:00PM  Alnylam Initiates Extension Study on ALN-AT3 for Hemophilia
Oct-06-15 05:30AM  Nexvet to Host Animal Health Symposium in New York City GlobeNewswire
Oct-05-15 03:49PM  Hedge Funds Expect Big Things From 1 Of These 2 Sliding Biotechs at Insider Monkey
Oct-02-15 04:15PM  Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program +5.15%
04:10PM  BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
10:53AM  Nexvet Biopharma PLC Earnings Q4, 2015
Sep-29-15 05:30AM  Nexvet Receives FY2015 Cash Refund of $3.2 Million GlobeNewswire
Sep-28-15 02:00PM  Genomic Health Posts Positive Breast Cancer Trial Results
Sep-21-15 01:30PM  Neogenomics Hits a 52-Week High on Cancer-Testing Deal -6.08%
Sep-17-15 06:03AM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-16-15 05:30AM  Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support GlobeNewswire
Sep-03-15 05:15PM  NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
Nexvet Biopharma public limited company, a clinical-stage biopharmaceutical company, focuses on developing and commercializing species-specific biologics. Its product candidates include Ranevetmab, a monoclonal antibody (mAb) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs; and Frunevetmab, a mAb that targets NGF inhibitor for the control of pain associated with degenerative joint disease, including osteoarthritis in cats. The company is also developing NV-03, a mAb targeting NGF that is being evaluated as a therapy for chronic joint pain in horses. In addition, it has research and development collaboration with Zenoaq for applying PETization technology to convert mAb candidates into species-specific candidates in the areas of immuno-oncology, inflammation, and allergy. Nexvet Biopharma public limited company is headquartered in Tullamore, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanna AshrafDirectorJul 01Option Exercise0.133,60045016,020Jul 05 12:28 PM
Gunn George WDirectorJul 01Option Exercise0.133,60045042,600Jul 05 12:22 PM
Lismore Damian T.Chief Financial OfficerJul 01Option Exercise0.137,07988521,239Jul 05 12:18 PM
Lismore Damian T.Chief Financial OfficerJul 01Option Exercise0.1334,0004,25067,750Jul 05 12:18 PM
Heffernan MarkChief Executive OfficerJul 01Option Exercise0.1360,6437,580109,810Jul 05 12:11 PM
PATEL RAJIV AMember of Group Owning 10%Jul 01Option Exercise0.133,60045013,580Jul 05 05:49 PM
PAYNE JOHN BERNARDDirectorJul 01Option Exercise0.133,60045010,800Jul 05 01:56 PM
Kilty Cormac GDirectorJul 01Option Exercise0.133,60045010,800Jul 05 01:51 PM
HORN JURGENChief Product Development OfcrJul 01Option Exercise0.1315,7501,96915,750Jul 05 01:39 PM
Farrell Geraldine TVP Operations, General CounselJul 01Option Exercise0.139,0601,13333,180Jul 05 01:30 PM
Farrell Geraldine TVP Operations, General CounselJul 01Option Exercise0.1312,3401,54318,980Jul 05 01:30 PM
Brown Christopher NigelDirectorJul 01Option Exercise0.133,6004507,200Jul 05 01:20 PM
McCracken Joseph SDirectorJul 01Option Exercise0.133,60045016,400Jul 05 12:59 PM
Hanna AshrafDirectorJun 30Option Exercise0.135006312,420Jul 05 12:28 PM
Gunn George WDirectorJun 30Option Exercise0.135006339,000Jul 05 12:22 PM
PATEL RAJIV AMember of Group Owning 10%Jun 30Option Exercise0.13500639,980Jul 05 05:49 PM
McCracken Joseph SDirectorJun 30Option Exercise0.135006312,800Jul 05 12:59 PM
PATEL RAJIV AMember of Group Owning 10%Mar 31Option Exercise0.13500639,480Apr 03 02:03 PM
McCracken Joseph SDirectorMar 31Option Exercise0.135006312,300Apr 04 11:23 AM
Hanna AshrafDirectorMar 31Option Exercise0.135006311,920Apr 04 11:20 AM
Gunn George WDirectorMar 31Option Exercise0.135006338,500Apr 04 11:16 AM
McCracken Joseph SDirectorDec 31Option Exercise0.135006311,800Jan 03 07:38 PM
Hanna AshrafDirectorDec 31Option Exercise0.135006311,420Jan 03 07:34 PM
Gunn George WDirectorDec 31Option Exercise0.135006338,000Jan 03 07:29 PM
PATEL RAJIV AMember of Group Owning 10%Dec 31Option Exercise0.13500638,980Jan 04 10:57 AM
McCracken Joseph SDirectorSep 30Option Exercise0.135006311,300Oct 04 03:52 PM
Hanna AshrafDirectorSep 30Option Exercise0.135006310,920Oct 04 03:47 PM
Gunn George WDirectorSep 30Option Exercise0.135006337,500Oct 04 03:44 PM
PATEL RAJIV AMember of Group Owning 10%Sep 30Option Exercise0.13500638,480Oct 04 09:26 AM